|
Name |
Eurocristatine
|
Molecular Formula | C32H36N6O4 | |
IUPAC Name* |
(1R,4R,7S,9R)-9-[(1R,4R,7S,9R)-3,6-dioxo-4-propan-2-yl-2,5,16-triazatetracyclo[7.7.0.02,7.010,15]hexadeca-10,12,14-trien-9-yl]-4-propan-2-yl-2,5,16-triazatetracyclo[7.7.0.02,7.010,15]hexadeca-10,12,14-triene-3,6-dione
|
|
SMILES |
CC(C)[C@@H]1C(=O)N2[C@@H](C[C@]3([C@@H]2NC4=CC=CC=C43)[C@]56C[C@H]7C(=O)N[C@@H](C(=O)N7[C@H]5NC8=CC=CC=C68)C(C)C)C(=O)N1
|
|
InChI |
InChI=1S/C32H36N6O4/c1-15(2)23-27(41)37-21(25(39)35-23)13-31(17-9-5-7-11-19(17)33-29(31)37)32-14-22-26(40)36-24(16(3)4)28(42)38(22)30(32)34-20-12-8-6-10-18(20)32/h5-12,15-16,21-24,29-30,33-34H,13-14H2,1-4H3,(H,35,39)(H,36,40)/t21-,22-,23+,24+,29+,30+,31-,32-/m0/s1
|
|
InChIKey |
VKGJCECPEIOHGI-VYWSVDQRSA-N
|
|
Synonyms |
Eurocristatine; (+)-Eurocristatine; J3.521.376G
|
|
CAS | NA | |
PubChem CID | 132566179 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 568.7 | ALogp: | 3.9 |
HBD: | 4 | HBA: | 6 |
Rotatable Bonds: | 3 | Lipinski's rule of five: | Rejected |
Polar Surface Area: | 123.0 | Aromatic Rings: | 8 |
Heavy Atoms: | 42 | QED Weighted: | 0.452 |
Caco-2 Permeability: | -5.464 | MDCK Permeability: | 0.00001880 |
Pgp-inhibitor: | 0.979 | Pgp-substrate: | 0.939 |
Human Intestinal Absorption (HIA): | 0.909 | 20% Bioavailability (F20%): | 0.018 |
30% Bioavailability (F30%): | 0.999 |
Blood-Brain-Barrier Penetration (BBB): | 0.056 | Plasma Protein Binding (PPB): | 93.76% |
Volume Distribution (VD): | 0.682 | Fu: | 4.57% |
CYP1A2-inhibitor: | 0.002 | CYP1A2-substrate: | 0.043 |
CYP2C19-inhibitor: | 0.407 | CYP2C19-substrate: | 0.358 |
CYP2C9-inhibitor: | 0.779 | CYP2C9-substrate: | 0.079 |
CYP2D6-inhibitor: | 0.014 | CYP2D6-substrate: | 0.093 |
CYP3A4-inhibitor: | 0.874 | CYP3A4-substrate: | 0.494 |
Clearance (CL): | 3.012 | Half-life (T1/2): | 0.145 |
hERG Blockers: | 0.004 | Human Hepatotoxicity (H-HT): | 0.96 |
Drug-inuced Liver Injury (DILI): | 0.923 | AMES Toxicity: | 0.024 |
Rat Oral Acute Toxicity: | 0.865 | Maximum Recommended Daily Dose: | 0.504 |
Skin Sensitization: | 0.533 | Carcinogencity: | 0.013 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.004 |
Respiratory Toxicity: | 0.033 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC005881 | 0.674 | D0J7XL | 0.303 | ||||
ENC004848 | 0.411 | D0L7LC | 0.278 | ||||
ENC001500 | 0.407 | D09NNH | 0.249 | ||||
ENC002594 | 0.378 | D0M2YE | 0.247 | ||||
ENC003490 | 0.376 | D02XIY | 0.243 | ||||
ENC003381 | 0.372 | D0K4CQ | 0.236 | ||||
ENC003176 | 0.367 | D01TSI | 0.236 | ||||
ENC004849 | 0.366 | D0E0RY | 0.233 | ||||
ENC002971 | 0.361 | D0W7RJ | 0.232 | ||||
ENC003382 | 0.361 | D05MQK | 0.232 |